氟哌啶醇制剂心血管系统安全性风险的分析及思考

doi:10.19803/j.1672-8629.20220137

摘要/Abstract

摘要： 目的了解氟哌啶醇制剂的安全性风险,为临床合理用药提供参考。方法对国家药品不良反应监测数据库2004年1月1日至2019年12月31日和国内外数据库建库至2020年5月31日中涉及氟哌啶醇的相关不良反应数据及国内外药品监管机构发布的关于氟哌啶醇相关风险控制措施等资料进行整理与分析。结果我国药品不良反应监测数据库共收到怀疑和并用药品涉及氟哌啶醇制剂的药品不良反应报告共13 936例,其中涉及心血管系统624例次,严重不良反应111例次;国内外文献报道等均提示了氟哌啶醇制剂的心血管相关不良反应风险。结论建议督促药品上市许可持有人加强氟哌啶醇制剂的不良反应监测和评价工作,及时修订产品说明书,密切监测用药风险,促进广大医护人员及患者合理用药。

关键词: 氟哌啶醇, 心血管风险, 药品不良反应, 监管措施

Abstract: Objective To analyze the risk of haloperidol preparations so as to provide reference for clinical rational drug use. Methods The reports about adverse drug reactions (ADR) induced by haloperidol that were collected in China adverse drug reaction database from, January 1, 2004 to December 31, 2019 as well as those collected in domestic and foreign database from inception to May 31, 2020, and the relevant risk control measures for haloperidol issued by domestic and foreign drug regulatory agencies were retrieved and analyzed. Results A total of 13 936 reports of adverse drug reactions involving haloperidol preparations were received the China Adverse Drug Reaction Monitoring Database for suspected and concurrent use of drugs including 624 cases involving the cardiovascular system and 111 cases of serious adverse reactions. The risk of cardiovascular-related adverse reactions of haloperidol preparations was suggested by domestic and foreign literature reports. Conclusion It is recommended that regulatory authorities urge the drug marketing authorization holders to strengthen the monitoring and evaluation of adverse reactions of haloperidol preparations, revise product instructions in a timely manner, and promote the rational use of drugs by medical staff and patients.

Key words: haloperidol, cardiovascular-related adverse reactions, adverse drug reaction, regulatory measures

中图分类号:

R971
R994.11

吴晨, 刘翠丽, 王涛. 氟哌啶醇制剂心血管系统安全性风险的分析及思考[J]. 中国药物警戒, 2022, 19(10): 1100-1102.

WU Chen, LIU Cuili, WANG Tao. Cardiovascular safety of haloperidol preparations[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.

参考文献

[1] ZHANG RK.Antipsychotic Drug Research[C]. Proceedings of the 13th National Symposium on Integrated Traditional Chinese and Western Medicine on Mental Illness, 2014: 246-249.
[2] NMPA. Notice on the publication of the second batch of the catalog of chemical drug instructions Drug Administration Note Letter (No. 58 of2002) [EB/OL].(2002-02-05)[2022-03-31]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20020205010101554.html.
[3] NMPA. Data Search[EB/OL] .[2022-07-08] . https://www.nmpa.gov.cn/datasearch/search-result.html.
[4] National Health Commission of the People's Republic of China. Notice on Issuing the National Essential Medicines List (2018 Edition) [EB/OL]. (2018-10-25) [2022-03-31]. http://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a3940d08d996b588d941631.shtml.
[5] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume II(中华人民共和国药典,二部)[M]. Beijing: China Medical Science Press, 2020.
[6] NMPA. Announcement of the State Drug Administration on the Revision of the Instructions for Haloperidol Preparation (No. 40 of2021) [EB/OL]. (2021-03-15) [2022-03-31]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20210318094757129.html.
[7] IBRAHIM C, MCDONALD D, VASCO M, et al.Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi[J]. BMC Res Notes, 2019, 12(1): 376.
[8] REYNOLDS GP, KIRK SL.Metabolic side efects of antipsychotic drug treatment—pharmacological mechanisms[J]. Pharmacol Ther, 2010, 125(1): 169-179.
[9] NIJBOER H, LEFEBER G, MACLULLICH A, et al.Erratum to: haloperidol use among elderly patients undergoing surgery: a retrospective 1-year study in a hospital population[J]. Drugs - Real World Outcomes, 2016, 3(2): 239.
[10] ESSALI A, TURKMANI K, ABOUDAMAAH S, et al. Haloperidol discontinuation for people with schizophrenia[J]. Cochrane Database Syst Rev, 2019, 21(4): CD011408.
[11] PIERDONÁ GF, PAIVA CJRL, PAIVA CDML, et al.Haloperidol-induced preclinical tardive dyskinesia model in rats[J]. Curr Protoc Neurosci, 2019, 88(1): e68.
[12] VORST MJDL, NEEFJES ECW, BODDAERT MSA, et al. Olanzapine Versus Haloperidol for treatment of delirium in patients with advanced cancer: a phase iii randomized clinical trial[J]. Oncologist, 2020, 25(3): e570-e577.
[13] HE HJ.Haloperidol causes severe extrapyramidal adverse reactions in pediatric patients.[J]. Chinese Journal of Drug Abuse Prevention and Treatment(中国药物滥用防治杂志), 2006, 12(3): 168.
[14] ZHU CY.Comparison of extraconal response and EKG changes due to high and low doses of haloperidol treatment[J]. Sichuan Mental Health(四川精神卫生), 1994(1): 57.
[15] YUAN SM.A case of cardiac rhythm disturbance caused by haloperidol[J]. Pediatric Emergency Medicine(小儿急救医学), 1994(2): 65.
[16] WU ZF, WANG SM, LIU YP, et al.A case of high atrioventricular block caused by haloperidol[J]. Journal of Clinical Military Medicine(临床军医杂志), 2004(3): 49.
[17] ZHOU GB.Electrocardiographic observations in patients taking haloperidol[J]. Heilongjiang Pharmaceutical Science(黑龙江医药科学), 2002, 25(2): 95.
[18] LI K, WANG ST, LIANG F, et al.Effect of haloperidol and olanzapine on electrocardiographic QTc[J]. China Medical Frontier(中国医疗前沿), 2013, 8(21): 67-68.
[19] YU T, JU HZ.Report of three cases of malignant syndrome[J]. Journal of Psychiatry(精神医学杂志), 2014, 27(2): 142.
[20] LIU HY, JIANG LJ, LI D, et al.Report of a case of malignant symptom cluster caused by intramuscular injection of haloperidol[J]. Jilin Medicine Journal(吉林医学), 2001(4): 254.
[21] ZHANG XP.Side effects of haloperidol treatment in 138 cases of schizophrenia[J]. Chinese Journal of Neuropsychiatric Disorders(中国神经精神疾病杂志), 1983(5): 298-300.
[22] WANG HY, CHEN H.Analysis of the characteristics of liver injury caused by haloperidol administration in psychiatric patients with different blood groups[J]. Journal of Practical Liver Diseases(实用肝脏病杂志), 2016, 19(6): 722-723.
[23] CHEN Q, XU ZC, ZHAO LP, et al.A case of acute renal failure caused by haloperidol[J]. China Pharmacist(中国药师), 2004, 7(4): 296-297.
[24] LI ZZ, HU ZY, TIAN HH.Effect of antipsychotic treatment on early renal function[J]. Modern Practical Medicine(现代实用医学), 2007, 19(10): 805-806.
[25] WANG SX, ZENG T.Report of a case of serious cardiac adverse reaction caused by low-dose haloperidol[J]. Shandong Psychiatry(山东精神医学),1994(1): 57.
[26] CAO GY, WANG CG, CHEN MH, et al.A case study in the literature of rhabdomyolysis caused by antipsychotic drugs[J]. Chinese Journal of Pharmacy(中国药学杂志), 2019, 54(18): 1527-1533.
[27] FDA. Information on Conventional Antipsychotics[EB/OL].(2008-06-16)[2020-03-25]. https://www.fda.gov/drugs/drug-safety-and-availability.
[28] FDA. Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate) [EB/OL].(2007-09)[2020-03-25]. https://www.fda.gov/drugs/drug-safety-and-availability.
[29] Japan Pharmaceutical Association. Drug Safety Update(No.168). [EB/OL].(2008-04)[2020-03-25]. https://www.pmda.go.jp/dsu/dsu_index.html.
[30] Japan Pharmaceutical Association. Drug Safety Update(No.198). [EB/OL].(2011-04)[2020-03-25]. https://www.pmda.go.jp/dsu/dsu_index.html.
[31] NMPA. Laws&Regulations[EB/OL].[2022-03-31]. https://www.nmpa.gov.cn/xxgk/fgwj/index.html.